Newsletter Tool

Today’s Big News

Aug 23, 2024

Biopharma VC hits highest quarterly level since 2022, but challenges in exit landscape remain

After $213M round, gene editing biotech Tome shrinks operations as investor sentiment worsens

Bicara and Zenas file for IPOs to push late-phase prospects toward finish line

Despite mixed market, a venture capital revival could be coming in Europe: PitchBook

Chutes & Ladders—BioMarin builds executive team with biotech vets

What Chevron’s overturn means for biopharma

Featured

Biopharma VC hit highest quarterly level since 2022, but challenges in exit landscape remain

By Gabrielle Masson

Venture capital in biopharma rose to $9.2 billion across 215 deals in the second quarter of this year, reaching the highest funding level since the same quarter in 2022.

After $213M round, gene editing biotech Tome shrinks operations as investor sentiment worsens

By Gabrielle Masson

After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome Biosciences is making cuts.

Bicara and Zenas file for IPOs to push late-phase prospects toward finish line

By Nick Paul Taylor

Bicara Therapeutics and Zenas Biopharma have provided fresh impetus to the IPO market with filings that illustrate what newly public biotechs may look like in the back half of 2024.

What’s Next for Biotech? Join Fierce Biotech Editors in Boston at Fierce Biotech Summit

Despite mixed market, a venture capital revival could be coming in Europe: PitchBook

By Fraiser Kansteiner

While the biotech investment scene in Europe has shrunk somewhat following a COVID-19 funding boom in 2021, a new report from PitchBook suggests venture capital firms looking at opportunities across the pond could soon have more cash to spare.

Chutes & Ladders—BioMarin builds executive team with biotech vets

By Darren Incorvaia,Zoey Becker,Gabrielle Masson

The coastal California biotech BioMarin is bringing two biotech vets on board to lead its new-look R&D and deals teams.

What Chevron’s overturn means for biopharma

By Ayla Ellison,Kevin Dunleavy

This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry.

FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds

By Angus Liu

The FDA will hold an advisory committee meeting on Sept. 26 to consider whether approvals for checkpoint inhibitors in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma—as well as in esophageal squamous cell carcinoma—should be restricted based on a tumor’s PD-L1 expression.

As sales climb, Jazz's Epidiolex falls short in Japanese study in treatment-resistant epilepsies

By Fraiser Kansteiner

On Friday, Jazz revealed that its Epidiolex oral solution failed to mass muster in a late-stage study when used as an adjunct treatment for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC) in young Japanese patients.

Fierce Pharma Asia—J&J's Tagrisso challenger; Merck's revised Kelun deal; The next biosecurity frontier

By Angus Liu

As part of a J&J combo, Yuhan's Lazcluze has become the first Korea-developed novel cancer drug to be approved by the FDA. Merck has optioned in on one Kelun Biotech ADC but returned another. A few U.S. lawmakers have asked the FDA to examine clinical trials involving sites at Chinese military hospitals. And more.

Fierce podcasts

Don’t miss an episode

What Chevron’s overturn means for biopharma

This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry.

How incentives engage and keep patients healthy

The TROP2 race for supremacy

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.